Capricor completes HOPE-3 enrollment; Q3 net loss $6.4M, cash $28.5M

CAPRICOR THERAPEUTICS, INC.

2023-Q3 EPS reported -$0.85 revenue$13,089,977

Completed targeted enrollment for HOPE-3 Phase 3 trial of CAP-1002 in Duchenne muscular dystrophy; interim futility analysis expected Q4 2023.
FDA affirmed alignment on HOPE-3 design; BLA submission planned supported by Cohort A results.
Q3 revenue $6.2M (from Nippon Shinyaku upfront recognition) vs $1.6M prior year; net loss $6.4M flat YoY.
Cash $28.5M at Sept 30; subsequent $23M registered direct offering with Nippon Shinyaku extends runway into 2025.
Appointed Michael Kelliher (Amgen/Horizon) to Board of Directors; advancing StealthX exosome platform.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CAPRICOR THERAPEUTICS, INC. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial results for the third quarter ended September 30, 2023 and provided a corporate update.

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

CAPRICOR THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-019019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.